Piaopiao Li

Piaopiao Li,

Graduate Student

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 328-2540
Business Email: piaopiao.li@ufl.edu

About Piaopiao Li

Piaopiao Li is a Ph.D. student at the Department of Pharmaceutical Outcomes and Policy. She received his bachelor’s degree in pharmacy and master’s degree in pharmaceutical science from Peking University in China. She worked as a clinical research associate at Johnson & Johnson in China. Piaopiao’s research interests lay mainly in the field of pharmacoeconomics and health services research. Her current research interests are in diabetes, microsimulation, and econometrics methods.

Related Links:

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-0941-5563

Areas of Interest
  • Diabetes
  • microsimulation
  • pharmacoeconomics

Publications

2024
Incremental burden on health‐related quality of life, health service utilization and direct medical expenditures associated with cognitive impairment among non‐institutionalized people with diabetes aged 65 years and older
Diabetes, Obesity and Metabolism. 26(1):275-282 [DOI] 10.1111/dom.15313.
2024
Some patients with type 2 diabetes may benefit from intensive glycaemic and blood pressure control: A post‐hoc machine learning analysis of ACCORD trial data
Diabetes, Obesity and Metabolism. 26(4):1502-1509 [DOI] 10.1111/dom.15453. [PMID] 38297986.
2023
Association between Antidepressants and Dementia Risk in Older Adults with Depression: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine. 12(19) [DOI] 10.3390/jcm12196342. [PMID] 37834986.
2023
Changes in racial and ethnic disparities in glucose-lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005-2018.
Diabetes, obesity & metabolism. 25(2):516-525 [DOI] 10.1111/dom.14894. [PMID] 36251173.
2023
The role of health system penetration rate in estimating the prevalence of type 1 diabetes in children and adolescents using electronic health records
Journal of the American Medical Informatics Association. 31(1):165-173 [DOI] 10.1093/jamia/ocad194. [PMID] 37812771.
2022
Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.
Journal of diabetes and its complications. 36(3) [DOI] 10.1016/j.jdiacomp.2022.108132. [PMID] 35101326.
2022
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes.
Diabetes care. 45(2):e32-e33 [DOI] 10.2337/dc21-1800. [PMID] 35020817.
2021
A varied approach to left ventricular assist device follow-up improves cost-effectiveness.
Current medical research and opinion. 37(9):1501-1505 [DOI] 10.1080/03007995.2021.1948395. [PMID] 34181489.
2021
The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018.
Current medical research and opinion. 37(11):1875-1880 [DOI] 10.1080/03007995.2021.1971181. [PMID] 34429001.

Education

Ph.D.
2020-2025 · University of Florida
M.S.Pharm.
2016-2018 · Peking University
B.S.Pharm.
2012-2016 · Peking University

Contact Details

Phones:
Business:
(352) 328-2540
Emails:
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610
Business Street:
Room 3334
FL
1225 Center Drive, HPNP Building
Gainesville FL 32610